There are currently 26 active clinical trials seeking participants for Alzheimer's Disease research studies. The states with the highest number of trials for Alzheimer's Disease participants are Florida, California, New York and Arizona.
Alzheimer's Prevention Registry: A Program to Accelerate Enrollment Into Studies
NCT02022943
Recruiting
The Alzheimer's Prevention Registry (www.endALZnow.org) will collect contact and demographic information on individuals. The objective is to provide information the latest news and advances in Alzheimer's prevention research, and to inform enrollees about research studies in their community. Enrolled individuals will receive regular email communications. As research studies become available, individuals will be notified via email with information as to how proceed should they be interested. Regi... Read More
Gender:
ALL
Ages:
Between 18 years and 110 years
Trial Updated:
06/27/2025
Locations: Banner Alzheimer's Institute, Phoenix, Arizona
Conditions: Alzheimer's Disease, Dementia
Register for Updates
A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)
NCT06653153
Recruiting
The purpose of this study is to measure the difference in time to developing or worsening memory, thinking, or functional problems due to Alzheimer's disease occurring in participants receiving study drug compared to placebo. Participation could last up to 255 weeks including screening, a double-blind treatment period, and a double-blind observation period. In addition, eligible participants who receive placebo during the double-blind treatment period may choose to extend their study participat... Read More
Gender:
ALL
Ages:
Between 55 years and 80 years
Trial Updated:
06/24/2025
Locations: Parkway Medical Center, Birmingham, Alabama +292 locations
Conditions: Alzheimer's Disease
Register for Updates
A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)
NCT05462106
Recruiting
The purpose of this study is to assess the safety, tolerability, immunogenicity and pharmacodynamic effects of ACI-24.060 in subjects with prodromal Alzheimer's disease and in non-demented adults with Down syndrome.
Gender:
ALL
Ages:
Between 35 years and 85 years
Trial Updated:
06/11/2025
Locations: Barrow Neurological Institute, Phoenix, Arizona +18 locations
Conditions: Alzheimer's Disease, Prodromal Alzheimer's Disease, Amyloid Plaque, Beta-Amyloid, Alzheimer's Disease in Down Syndrome
Register for Updates
A Postmarketing Study of Lecanemab in South Korean Participants With Alzheimer's Disease
NCT06810960
Recruiting
The primary purpose of this study is to evaluate safety of lecanemab in the real-world clinical setting as reported by events of amyloid-related imaging abnormalities (ARIA)-edema (ARIA-E), ARIA-hemosiderin deposition (ARIA-H), symptomatic ARIA-E, symptomatic ARIA-H, and intracerebral hemorrhage (ICH) greater-than 1 centimeter (cm) in participants treated with lecanemab.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/30/2025
Locations: Eisai Trial Site #1, Nutley, New Jersey
Conditions: Alzheimer's Disease
Register for Updates
Investigating the Impact of Duration and Amount of Light on the Circadian System Response - Aim 3
NCT06595030
Recruiting
Investigate the long-term impact of amount and duration of Tailored Lighting Intervention (TLI) obtained from Aims 1 and 2 on sleep, cognition, circadian marker, mood, and behavior in AD/ADRD patients. For this single-arm, randomized, placebo-controlled study, the researchers plan to recruit 100 participants who will experience either the active TLI or the placebo for 6 months.
Gender:
ALL
Ages:
55 years and above
Trial Updated:
05/28/2025
Locations: Icahn School of Medicine at Mount Sinai, Menands, New York +1 locations
Conditions: Alzheimer's Disease, Mild Cognitive Impairment
Register for Updates
Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia
NCT06584357
Recruiting
Bio-Hermes-002 is a 120-day cross-sectional study that will result in a blood, CSF, retinal, digital, MRI, and PET brain imaging biomarker database that can be used to determine the primary objective. Digital biomarkers and blood-based biomarkers will be tested to determine whether a meaningful relationship exists between biomarkers alone or in combination with tau or amyloid brain pathology identified through PET images.
Gender:
ALL
Ages:
Between 60 years and 90 years
Trial Updated:
05/16/2025
Locations: JEM Research Institute, Atlantis, Florida +18 locations
Conditions: Mild Cognitive Impairment, Alzheimer's Disease, Alzheimer's Disease, Early Onset, Memory Loss, Memory Disorders, Memory Impairment
Register for Updates
Pulsed Electromagnetic Field Treatment With Dementia Patients
NCT06862557
Recruiting
An open label pilot study in mild to moderate AD/ADRD patients to assess the effects of treatment with ECHS AD/ADRD pulsed electromagnetic treatment device on disease progression. Enrolled patients will receive active devices. They will treat themselves at home three times a day for 15 minutes over 120 days. Primary end point is the The Alzheimer's Disease Assessment Scale-Cognitive Subscale. Participants will be followed-up for 9 months post-treatment.
Gender:
ALL
Ages:
Between 50 years and 100 years
Trial Updated:
05/15/2025
Locations: University of Miami, Boca Raton, Florida
Conditions: Alzheimer's Disease, Lewy Body Dementia, Vascular Dementia
Register for Updates
Study to Evaluate the Effects of NMRA-323511 Among Healthy Elderly and Adults With Agitation Associated With Dementia Due to Alzheimer's Disease
NCT06546995
Recruiting
This study consists of 2 parts, Part A and Part B. Part A is a single center, randomized, double-blind, placebo-controlled cohort designed to evaluate the safety, tolerability, and pharmacokinetics (PK) of NMRA-323511 among healthy elderly. Part B is a multicenter, randomized, double-blinded, placebo-controlled, parallel-group cohort to evaluate the safety, tolerability, and efficacy of NMRA-323511 among adults with Agitation Associated with Dementia due to Alzheimer's Disease. Part A consists... Read More
Gender:
ALL
Ages:
Between 55 years and 90 years
Trial Updated:
05/14/2025
Locations: Neumora Investigator Site, Chandler, Arizona +24 locations
Conditions: Alzheimer's Disease, Healthy Elderly
Register for Updates
TREAD: Time Restricted Eating Intervention for Alzheimer's Disease
NCT06548191
Recruiting
The goal of this clinical trial is to learn if restricting the time of eating to allow for prolonged fasting at night may reduce sleep disturbances, cognitive decay, and pathology in patients diagnosed with Mild Cognitive Impairment (MCI) or early to moderate Alzheimer's disease (AD). It will also learn about the feasibility of practicing 14 h of nightly fasting in this group of older adults. The main questions it aims to answer are: * Does prolonged nightly fasting of 14 h can reduce markers o... Read More
Gender:
ALL
Ages:
60 years and above
Trial Updated:
04/24/2025
Locations: Shiley Marcos Alzheimer's Disease Center, San Diego, California
Conditions: Mild Cognitive Impairment, Alzheimer Disease, Alzheimer's Disease
Register for Updates
A Clinical Trial of AAV2-BDNF Gene Therapy in Early Alzheimer's Disease and Mild Cognitive Impairment
NCT05040217
Recruiting
This is a first-in-human clinical trial to test whether a protein administered into the brain continuously by gene therapy, Brain-Derived Neurotrophic Factor (BDNF), will slow or prevent cell loss in the brains of people affected by Alzheimer's disease and Mild Cognitive Impairment. The protein may also activate cells in the brain that have not yet deteriorated. Gene therapy refers to the use of a harmless virus to have brain cells make the potentially protective protein, BDNF.
Gender:
ALL
Ages:
Between 50 years and 80 years
Trial Updated:
04/24/2025
Locations: University of California - San Diego, La Jolla, California +1 locations
Conditions: Alzheimer's Disease, Mild Cognitive Impairment
Register for Updates
Wake Forest Alzheimer's Disease Clinical Core
NCT03140865
Recruiting
Efforts to find treatments for AD have yielded only modest benefits, likely because longstanding AD pathological processes induce irreversible neurological compromise. These processes begin years before the onset of clinical symptoms. This possibility has been incorporated into a model describing stages of AD development, articulated by the NIA/Alzheimer's Association preclinical workgroup of which the Co-Director of the Kulynych Alzheimer's Research Center, Dr. Suzanne Craft, was a member. Acco... Read More
Gender:
ALL
Ages:
55 years and above
Trial Updated:
04/23/2025
Locations: Wake Forest Baptist Health, Winston-Salem, North Carolina
Conditions: Alzheimer's Disease, Mild Cognitive Impairment, Prediabetic State
Register for Updates
DIAN-TU Amyloid Removal Trial (ART) in Dominantly Inherited Alzheimer's Disease
NCT06384573
Recruiting
This is an open label study to treat dominantly inherited Alzheimer's disease (DIAD) mutation carrier participants from the DIAN-TU-001 gantenerumab Open Label Extension (OLE) period with lecanemab to determine the effects of amyloid removal on age of onset and clinical progression compared to external controls, if amyloid plaque as measured by amyloid PET can be fully removed in DIAD, and the effects of amyloid removal on biomarkers of disease progression.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/30/2025
Locations: University of Alabama in Birmingham, Birmingham, Alabama +5 locations
Conditions: Alzheimer's Disease, Dementia, Alzheimer's Disease, Familial
Register for Updates